

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENVON GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2389)

VOLUNTARY ANNOUNCEMENT – STRATEGIC COOPERATIVE FRAMEWORK AGREEMENT

This announcement is a voluntary announcement made by Genvon Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to inform the public of the updated business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 12 July 2015, the Company has entered into a strategic cooperative framework agreement (“**Strategic Cooperative Agreement**”) with Jangho Group Company Limited (“**Jangho**”), a company with its A shares listed on the Mainboard of the Shanghai Stock Exchange (stock code: 601886).

To the best knowledge, information and belief of the Board, and having made all reasonable enquiries, Jangho is an independent third party independent of the Company and its connected persons (as defined in the Listing Rules).

STRATEGIC COOPERATIVE FRAMEWORK AGREEMENT

Pursuant to the Strategic Cooperative Agreement, by leveraging on both parties’ strengths, both parties have agreed to form strategic partnership for the development of medical and healthcare related business, to give preference to each other for the strategic cooperation in respect of medical and healthcare management and services covering comprehensive aspects including project cooperation, capital operation, etc. Such strategic cooperation will capitalize the strengths of both the Group and Jangho, which will create synergies to drive the strategic development of both parties.

Summary of the cooperation is set out as follows:

1. Both parties have agreed to form strategic partnership in respect of medical and healthcare related business, which includes, but not limited to, the right to cooperate in relation to any underlying aspect such as capital operation;
2. Both parties will share resources including business and clients. They shall have the right to give preference to each other in relation to the development of the relevant project of medical and healthcare management and services;
3. Both parties have confirmed to provide support to each other in relation to capital operation such as private placing and asset reorganisation and give preference to each other when selecting strategic investor; and
4. Both parties have confirmed the proposed establishment of an associated company, through which the medical and healthcare related cooperation business will be commenced. The registered capital of the associated company shall be less than HK\$100 million, of which each of the Company and Jangho shall hold 50% interests respectively. With the associated company acting as a platform for the cooperation of both parties in various aspects including specialty hospital construction and management, medical and healthcare services, both parties have committed to providing full support by leveraging on each other's advantages. A separate agreement with specific terms to be contained therein shall be entered into between both parties.

INFORMATION ABOUT JANGHO

As a company with its A shares listed on the Mainboard of China, Jangho is a leading provider of comprehensive facade solutions covering curtain walls and interior design. Headquartered in Beijing, Jangho has a registered capital of RMB1.12 billion. It is one of the China's top 500 companies and China's top 500 private companies. Currently, Jangho has various subsidiaries, namely Beijing Jangho Curtain Wall Co., Ltd., Beijing Gangyuan Architectural Decoration Engineering Co., Ltd., Sundart Holdings Limited and Steve Leung Designers Ltd..

REASONS FOR, AND ADVANTAGES OF ENTERING INTO THE STRATEGIC FRAMEWORK AGREEMENT

The Directors considers that, through the strategic cooperative framework agreement, (i) both parties shall be able to form a win-win and sustainable strategic partnership, and integrate each other's advantages and resources so as to create higher commercial value for each other by implementing various projects; (ii) through continuous innovations on operation and management, both parties shall introduce internationally advanced medical management ideas and operating system. They can actively create new vision and model for medical and healthcare services by expediting expansion and industrial integration, which eventually builds up a medical and healthcare brand with the strongest competitiveness and the largest influence; and (iii) both parties intend to make investments in specialty hospital management services, medical devices and bio-medical in the coming three years through various ways like construction, equity participation and trusteeship, therefore, entering of this strategic cooperative framework agreement is in the interests of the Company and its shareholders as a whole.

GENERAL

As the strategic cooperative framework agreement is merely a framework agreement entered into between both parties, a formal and specific written cooperative agreement shall be entered into separately. The Strategic Cooperative Agreement may lead to but does not represent the signing of any formal and specific cooperative agreement, therefore, the shareholders and potential investors of the Company shall exercise cautions when dealing with the shares of the Company. Further announcement will be issued by the Company in due course to inform its shareholders and potential investors of any material development on the said matter.

Shareholders and potential investors of the Company shall exercise cautions when dealing with the shares of the Company.

By Order of the Board
Genvon Group Limited
Zhu Shi Xing
Chairman

Hong Kong, 13 July 2015

As at the date of this announcement, the Board comprises seven Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Hu Xiao Yong, Mr. Hu Shiang Chi, Mr. Wang Zheng Chun and Mr. Zhang Jing Ming; one Non-Executive Director, namely Mr. Robert Winslow Koepf and four Independent Non-Executive Directors, namely Mr. Xie Ming, Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin and Mr. Zhang Yun Zhou.